Emerging B-Cell Therapies in Systemic Lupus Erythematosus

References

• Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56:1251–1262. doi:10.1002/art.22510
   PubMed Web of Science ®Google Scholar
• Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus – an update. Curr Opin Immunol. 2012;24:651–657. doi:10.1016/j.coi.2012.10.004
   PubMed Web of Science ®Google Scholar
• D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369:587–596. doi:10.1016/S0140-6736(07)60279-7
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939. doi:10.1056/NEJMra071297
   PubMed Web of Science ®Google Scholar
• Askanase AD, Wallace DJ, Weisman MH, et al. Use of pharmacogenetics, enzymatic phenotyping and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol. 2009;36:89–95. doi:10.3899/jrheum.070968
   PubMed Web of Science ®Google Scholar
• Carneiro JR, Sato EI. Double blind, randomized, placebo-controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275–1279.
   PubMed Web of Science ®Google Scholar
• Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. J Biochem Cell Biol. 2010;42:543–550. doi:10.1016/j.biocel.2009.10.011
   PubMed Web of Science ®Google Scholar
• Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med. 2013;368:1528–1535. doi:10.1056/NEJMct1207259
   PubMed Web of Science ®Google Scholar
• Navarra S, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, Phase 3 trial. Lancet. 2011;377:721–731. doi:10.1016/S0140-6736(10)61354-2
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930. doi:10.1002/art.30613
   PubMed Web of Science ®Google Scholar
• Merrill JT, van Vollenhoven RF, Buyon JF, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicenter, randomized, double blind, placebo-controlled study. Ann Rheum Dis. 2016;75:332–340. doi:10.1136/annrheumdis-2015-207654
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus: 52-week data (APRIL-SLE randomized trial). Ann Rheum Dis. 2015;74:2006–2015. doi:10.1136/annrheumdis-2013-205067
   PubMed Web of Science ®Google Scholar
• Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus: results from a randomized, double blind, placebo-controlled trial. Ann Rheum Dis. 2018;77:883–889. doi:10.1136/annrheumdis-2018-213032
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:362–375. doi:10.1002/art.39856
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis. Arthritis Rheum. 2013;65:2368–2379. doi:10.1002/art.38037
   PubMed Web of Science ®Google Scholar
• Furie RA, Aroca G, Alvarez A, et al. A phase II randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis (abstract). Arthritis Rheumatol. 2019;71:1125–1134.
   PubMed Web of Science ®Google Scholar
• Masoud S, McAdoo SP, Bedi R, et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatol. 2018;57:1156–1161. doi:10.1093/rheumatology/key042
   PubMed Web of Science ®Google Scholar
• Merrill JT, June J, Koumpouras F, et al. Top-line results of a Phase 2, double blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb5871, in systemic lupus erythematosus (abstract). Arthritis Rheumatol. 2018;70:266–276.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Furie RA, Jones N, et al. Efficacy, safety, and pharmacodynamics effects of the Bruton’s tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus erythematosus: results of a phase 2 randomized controlled trial (abstract). Arthritis Rheumatol. 2019;71.
   Web of Science ®Google Scholar
• Ishii T, Tanaka Y, Kawakami A, et al. Multicenter double blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018;28:986–992. doi:10.1080/14397595.2018.1432331
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Schneider R, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365–373. doi:10.1038/nrrheum.2014.33
   PubMed Web of Science ®Google Scholar
• Ritterhouse LL, Crowe ST, Niewold TB, et al. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum. 2011;63:3931–3941. doi:10.1002/art.30598
   PubMed Web of Science ®Google Scholar
• Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453–2459. doi:10.1002/art.23678
   PubMed Web of Science ®Google Scholar
• Alexander T, Cheng Q, Klotsche J, et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol. 2018;48:1573–1579. doi:10.1002/eji.201847492
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles lupus assessment group’s disease activity index for patients with systemic lupus erythematosus. Rheumatol. 2005;44:902–906. doi:10.1093/rheumatology/keh624
   PubMed Web of Science ®Google Scholar
• Galarza C, Valencia D, Tobon GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol. 2008;34:124–128. doi:10.1007/s12016-007-8028-z
   PubMed Web of Science ®Google Scholar
• Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractor SLE with rituximab plus cyclophosphamide: clinical effects, serological changes and predictors of response. Ann Rheum Dis. 2007;67:330–334. doi:10.1136/ard.2007.079095
   PubMed Web of Science ®Google Scholar
• Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Long term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35:826–833.
   PubMed Web of Science ®Google Scholar
• Albert D, Dunham J, Khan S, et al. Varibility in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis. 2008;67:1724–1731. doi:10.1136/ard.2007.083162
   PubMed Web of Science ®Google Scholar
• Kamburova EG, Koenen HJPM, Boon L, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012;12:341–350. doi:10.1111/j.1600-6143.2011.03833.x
   PubMed Web of Science ®Google Scholar
• Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364–372. doi:10.1016/j.semarthrit.2011.06.004
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470–475. doi:10.1136/ard.2006.057885
   PubMed Web of Science ®Google Scholar
• Moroni G, Raffiotta F, Trezzi B, et al. Rituximab vs mycophenolate vs cyclophosphamide for induction therapy of active lupus nephritis: a clinical observational study. Rheumatol. 2014;53:1570–1577. doi:10.1093/rheumatology/ket462
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767–776. doi:10.1177/0961203309106174
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial (EXPLORER). Arthritis Rheum. 2010;62:222–233. doi:10.1002/art.27233
   PubMed Web of Science ®Google Scholar
• Rovin B, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study (LUNAR). Arthritis Rheum. 2012;64:1215–1226. doi:10.1002/art.34359
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B cell therapies in the treatment of adult systemic lupus erythematosus. Lupus. 2016;25:1086–1096. doi:10.1177/0961203316652491
   PubMed Web of Science ®Google Scholar
• Coco-Ibanez T, Loza-Santamaria E, Peg-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44:175–185. doi:10.1016/j.semarthrit.2014.04.002
   PubMed Web of Science ®Google Scholar
• Fernandez-Nebro A, de la Fuente J, Carreno L, et al. Multicenter longitudinal study of B lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21:1063–1076. doi:10.1177/0961203312446627
   PubMed Web of Science ®Google Scholar
• Pinto LF, Velasquez CJ, Prieto C, et al. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus. 2011;20:1219–1226. doi:10.1177/0961203311409273
   PubMed Web of Science ®Google Scholar
• Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016;25:617–626. doi:10.1177/0961203315622819
   PubMed Web of Science ®Google Scholar
• Guzman M, Hui-Yuen JS. Management of pediatric systemic lupus erythematosus: focus on belimumab. Drug Design Dev Ther. 2020;14:2503–2513. doi:10.2147/DDDT.S216193
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–1349. doi:10.1136/annrheumdis-2011-200937
   PubMed Web of Science ®Google Scholar
• Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838–844. doi:10.1136/annrheumdis-2012-202865
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a 52-week randomized, double blind, placebo controlled study. Arthritis Rheumatol. 2017;69:1016–1027. doi:10.1002/art.40049
   PubMed Web of Science ®Google Scholar
• Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomized, placebo-controlled trial. Ann Rheum Dis. 2020;79:1340–1348. doi:10.1136/annrheumdis-2020-217101
   PubMed Web of Science ®Google Scholar
• D’Cruz D, Maksimowicz-McKinnon K, Oates J, et al. Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study. Lupus Sci Med. 2019;6.
   Google Scholar
• Dooley A, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase III belimumab clinical trials in patients with SLE. Lupus. 2013;22:63–72. doi:10.1177/0961203312465781
   PubMed Web of Science ®Google Scholar
• Furie RA, Rovin BH, Joussai F, et al. Two-year, randomized controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117–1128. doi:10.1056/NEJMoa2001180
   PubMed Web of Science ®Google Scholar
• Atisha F, Malkiel S, Harris KM, et al. CALIBRATE: a phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2020. doi:10.1002/art.41466.
   Web of Science ®Google Scholar
• Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367–372. doi:10.1038/nrrheum.2016.18
   PubMed Web of Science ®Google Scholar
• Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24 month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118. doi:10.1136/lupus-2015-000118
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard-of-care therapy for up to 13 years in patients with systemic lupus erythematosus. Arthritis Rheum. 2019;71:1125–1134. doi:10.1002/art.40861
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42:2288–2295. doi:10.3899/jrheum.150470
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of belimumab administered in combination with rituximab to adult subjects with systemic lupus erythematosus (SLE) – BLISS-BELIEVE. Clinicaltrials.gov identifier: NCT 03312907, accessed 30 August 2020. 2020.
   Google Scholar
• A study of subcutaneous (sc) belimumab in pediatric participants with systemic lupus erythematosus (SLE). Clinicaltrials.gov identifier: NCT 04179032, accessed 30 August 2020. 2020.
   Google Scholar
• Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:300–309. doi:10.3899/jrheum.121368
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Navarra SV, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase II and III studies in patients with systemic lupus erythematosus. Lupus. 2013;22:144–154. doi:10.1177/0961203312469259
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz M, van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016;25:699–709. doi:10.1177/0961203315625119
   PubMed Web of Science ®Google Scholar
• Leblanc-Trudeau C, Masetto A, Bocti C. Progressive multifocal encephalopathy associated with belimumab in a patient with systemic lupus erythematosus. J Rheumatol. 2015;42:551–552. doi:10.3899/jrheum.140577
   PubMed Web of Science ®Google Scholar
• Raisch DW, Rafi JA, Chen C, et al. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse reporting system. Expert Opin Drug Saf. 2016;15:1003–1011. doi:10.1080/14740338.2016.1198775
   PubMed Web of Science ®Google Scholar
• Bernatksy S, BOivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–2557. doi:10.1002/art.21955
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52 week, phase III, multicenter, randomized, double blind, placebo-controlled study. Ann Rheum Dis. 2016;75:323–331. doi:10.1136/annrheumdis-2015-207653
   PubMed Web of Science ®Google Scholar
• Rovin B, Dooley MA, Radhakrishnan J, et al. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase III randomized, clinical trials. Lupus. 2016;25:1597–1601. doi:10.1177/0961203316650734
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24 week, multicenter, randomized, double blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70:266–276. doi:10.1002/art.40360
   PubMed Web of Science ®Google Scholar
• Morand E, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase IIb ADDRESS II study. Rheumatol. 2020;59:2930–2938. doi:10.1093/rheumatology/keaa029.
   PubMed Web of Science ®Google Scholar
• Gordon C, Wofsy D, Wax S, et al. Post hoc analysis of the phase II/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol. 2017;69:122–130. doi:10.1002/art.39809
   PubMed Web of Science ®Google Scholar
• Furie RA, Leon G, Thomas M, et al. A phase II, randomized, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74:1667–1675. doi:10.1136/annrheumdis-2013-205144
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double blind, placebo-controlled, multicenter studies (ALLEVIATE) and follow-up. Rheumatol. 2013;52:1313–1322. doi:10.1093/rheumatology/ket129
   PubMed Web of Science ®Google Scholar
• Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:326–337. doi:10.1038/nrrheum.2010.68
   PubMed Web of Science ®Google Scholar
• Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383:1149–1155. doi:10.1056/NEJMoa2023325
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol. 2008;180:361–371. doi:10.4049/jimmunol.180.1.361
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9:44–52. doi:10.1177/1756285615601933
   PubMed Web of Science ®Google Scholar
• A study to evaluate two doses of ocrelizumab in patients with active systemic lupus erythematosus (BEGIN). Clinicaltrials.gov identifier: NCT00539838, accessed 30 August 2020. 2020.
   Google Scholar
• A study of ocrelizumab in children and adolescents with relapsing-remitting multiple sclerosis. Clinicaltrials.gov identifier: NCT 04075266, accessed 30 August 2020. 2020.
   Google Scholar
• A study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis (O’HAND). Clinicaltrials.gov identifier: NCT04035005, accessed 30 August 2020. 2020.
   Google Scholar
• Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatol. 2017;56:1227–1237. doi:10.1093/rheumatology/kex067
   PubMed Web of Science ®Google Scholar
• Montillo M, O’Brien S, Tedeschi A, et al. Autoimmune haemolytic anaemia and immune mediated thrombocytopenia in the phase III RESONATE study of Ibrutinib vs Ofatumumab in relapsed/refractory chronic lymphocytic leukemia, including a case report. Blood. 2014;124:565. doi:10.1182/blood.V124.21.5654.5654
   Web of Science ®Google Scholar
• Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J. 2016;9:552–555. doi:10.1093/ckj/sfw022
   PubMed Web of Science ®Google Scholar
• Thornton CC, Ambrose N, Ioannou Y. Ofatumumab: a novel treatment for severe systemic lupus erythematosus. Rheumatol (Oxford). 2015;54:559–560. doi:10.1093/rheumatology/keu475
   PubMed Web of Science ®Google Scholar
• A study to evaluate the effect of XmAb5871 on disease activity in patients with IgG4-related disease. Clinicaltrials.gov identifier: NCT 02725476, accessed 30 August 2020. 2020.
   Google Scholar
• Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–233. doi:10.1038/361226a0
   PubMed Web of Science ®Google Scholar
• Satterthwaite AB. Bruton’s Tyrosine Kinase, a component of B cell signaling pathways, has multiple roles in the pathogenesis of lupus. Front Immunol. 2018;8:1986. doi:10.3389/fimmu.2017.01986
   PubMed Web of Science ®Google Scholar
• Chalmers SA, Glynn E, Garcia SJ, et al. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clin Immunol. 2018;197:205–218. doi:10.1016/j.clim.2018.10.008
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437. doi:10.1056/NEJMoa1509388
   PubMed Web of Science ®Google Scholar
• Hutcheson J, Vanarsa K, Bashmakov A, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther. 2012;14:R243. doi:10.1186/ar4086.
   PubMed Web of Science ®Google Scholar
• MSC2364447C phase Ib in systemic lupus erythematosus. Clinicaltrials.gov identifier: NCT02537028, accessed 30 August 2020. 2020.
   Google Scholar
• A study of AC0058TA in patients with systemic lupus erythematosus. Clinicaltrials.gov identifier: NCT03878303, accessed 30 August 2020. 2020.
   Google Scholar
• Richardson PG, Sonnevald P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498. doi:10.1056/NEJMoa043445
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907–4916. doi:10.1182/blood-2005-08-3531
   PubMed Web of Science ®Google Scholar
• Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748–755. doi:10.1038/nm1763
   PubMed Web of Science ®Google Scholar
• Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64:493–503. doi:10.1002/art.33333
   PubMed Web of Science ®Google Scholar
• Seavey MM, Lu LD, Stump KL, et al. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012;12:257–270. doi:10.1016/j.intimp.2011.11.019
   PubMed Web of Science ®Google Scholar
• Segarra A, Arredondo KV, Jaramillo J, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus. 2020;29:118–125. doi:10.1177/0961203319896018
   PubMed Web of Science ®Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1474–1478. doi:10.1136/annrheumdis-2014-206016
   PubMed Web of Science ®Google Scholar
• Chamberlain C, Colman PJ, Ranger AM, et al. Repeated administration of dapirolizumab pegol in a randomized phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017;76:1837–1844. doi:10.1136/annrheumdis-2017-211388
   PubMed Web of Science ®Google Scholar
• Marino E, Grey ST. B cells as effectors and regulators of autoimmunity. Autoimmunity. 2012;45:377–387. doi:10.3109/08916934.2012.665527
   PubMed Web of Science ®Google Scholar
• Louis Bridges S, White DW, Worthing AB, et al. The science behind biosimilars: entering a new era of biologic therapy. Arthritis Rheumatol. 2018. doi:10.1002/art.40388.
   Web of Science ®Google Scholar